Clinical trials
Waldenström Macroglobulinemia clinical trials
Below are recruiting waldenström macroglobulinemia clinical trials, each written for real people, not researchers. We’re tracking 18 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06986174RecruitingPhase 2
Pacritinib for relapsed or refractory Waldenström macroglobulinemia
This trial tests a pill called pacritinib for people with Waldenström macroglobulinemia that has come back or stopped responding to other treatments. The goal is to see if pacritinib can help control the disease by blocking certain proteins that cancer cells need to grow.
Boston, MassachusettsAges 18 years+ - NCT07471074Recruiting
Study of stem cells in Waldenström macroglobulinemia
This study looks at bone marrow stem cells in people with Waldenström macroglobulinemia (WM). It aims to understand how these cells work and may help improve future treatments for WM.
AmiensAges 18 years+ - NCT05326308Recruiting
Zanubrutinib treatment in several blood cancers
This non-interventional study looks at outcomes for people with certain slow-growing blood cancers who are treated with zanubrutinib, with specific add-on use of obinutuzumab for follicular lymphoma. It may help doctors understand how this treatment is working in real-world care across several cancer types.
SalzburgAges 18 years+ - NCT03697356RecruitingPhase 2
Rituximab plus VRD, then lenalidomide to treat Waldenstrom’s
This Phase 2 study tests a treatment plan that starts with rituximab plus VRD (bortezomib, and reduced-dose drugs in the VRD group), then uses lenalidomide for maintenance to help control Waldenstrom’s macroglobulinemia. It may help people who need treatment because their disease is measurable.
Busan, Sue-guAges 19 years+ - NCT05640102Recruiting
Study of zanubrutinib in Waldenström macroglobulinemia
This is an observational study that follows people with Waldenström macroglobulinemia (WM) to learn how well zanubrutinib works and how safe it is. Your results will be tracked in relation to your disease features, including a blood/marrow marker called MYD88.
Huntsville, AlabamaAges 18 years+ - NCT05099471RecruitingPhase 2
Venetoclax plus rituximab for Waldenström’s macroglobulinemia
This Phase 2 study tests whether the combination of venetoclax and rituximab works better for Waldenström’s macroglobulinemia (WM) than expected from standard approaches. It is for adults with WM who have symptoms or organ/health problems caused by the disease.
BielefeldAges 18 years+ - NCT04898647Recruiting
Study of blood thickness in Waldenström’s disease
This study looks at “hyperviscosity,” meaning very thick blood, in people with Waldenström macroglobulinemia (WM). Your results may help doctors better understand who needs treatment and what tests should be used, even if thick blood is not found.
AmiensAges 18 years+ - NCT04893564Recruiting
Testing blood DNA after 6 months of Waldenström treatment
This study looks at a blood test called circulating tumor DNA, measured after 6 months of treatment, to see how well it predicts outcomes in people with Waldenström macroglobulinemia. It may help doctors better judge who is responding and who may need treatment adjustments earlier.
AmiensAges 18 years+ - NCT07231952RecruitingPhase 2
Pirtobrutinib, venetoclax, and rituximab for Waldenstrom's macroglobulinemia
This trial tests a combination of three drugs (pirtobrutinib, venetoclax, and rituximab) for people newly diagnosed with Waldenstrom's macroglobulinemia who have not had treatment before and need therapy for their symptoms.
Boston, MassachusettsAges 18 years+ - NCT05006716RecruitingPhase 1/Phase 2
Testing a new drug for certain B-cell blood cancers
This Phase 1/2 trial studies the safest dose and then effectiveness of BGB-16673 in people with specific B-cell malignancies. It may help by targeting cancer cells in these blood cancers, especially after other treatments like BTK inhibitors.
Birmingham, AlabamaAges 18 years+ - NCT07609862RecruitingPhase 1/Phase 2
Rocbrutinib and Lacutoclax for B-Cell Blood Cancers
This trial tests a combination of two new drugs (rocbrutinib and lacutoclax) to treat B-cell lymphomas and leukemias. The goal is to see if this combination works better than standard treatments, especially for patients whose cancer has come back or stopped responding to previous therapy.
TianjinAges 18 years+ - NCT07424833RecruitingPhase 1
Study of APG-3288 for Relapsed/Refractory Blood Cancers
This trial is testing a new drug called APG-3288 for people with certain relapsed or treatment-resistant blood cancers (like CLL/SLL, DLBCL, MCL, WM, MZL, or FL). You may qualify if you've tried at least 2 prior treatments and are looking for a new option.
Los Angeles, CaliforniaAges 18 years+ - NCT05294731RecruitingPhase 1/Phase 2
Study drug for certain B-cell cancers in Chinese participants
This early-stage study tests a new medicine (BGB-16673) that targets B-cell cancer cells in people with specific lymphoma or related blood cancers. It aims to see how well the drug can control the cancer and what side effects it causes, especially in Chinese participants.
Bengbu, AnhuiAges 18 years+ - NCT07249905RecruitingPhase 1/Phase 2
Testing MDX2003 for people with relapsed B-cell lymphoma
This trial is testing a new drug, MDX2003, for people with certain types of lymphoma that have come back after at least two prior treatments. It aims to see how safe the drug is and if it can shrink tumors.
Richmond, VictoriaAges 18 years+ - NCT07173790Enrolling by invitation
Watch and Wait in Slow-Growing Lymphoma
This study looks at how people with slow-growing lymphomas (like CLL, MZL, FL, or WM) feel during watchful waiting — when they are not on active treatment. It aims to see if patients are more anxious or worried, and how to best support them.
Seoul, Gangnam-guAges 19 years+ - NCT06043011Recruiting
Registry for non-Hodgkin lymphoma patients on systemic therapy
This registry tracks people with non-Hodgkin lymphoma who are starting a new line of systemic therapy. It collects information to better understand how treatments work in real life, and optionally asks you to fill out surveys about your symptoms and quality of life.
Freiburg im BreisgauAges 18 years+ - NCT07160270Recruiting
Nerve problems in Waldenström's macroglobulinemia
This study looks at how common nerve problems (peripheral neuropathy) are in people with Waldenström's macroglobulinemia (WM), and how to best diagnose them. It aims to help doctors find nerve issues earlier and improve care.
København ØAges Any age - NCT04061512RecruitingPhase 2/Phase 3
Rituximab plus ibrutinib versus standard steroids plus rituximab
This trial compares two starting treatment plans for Waldenström’s macroglobulinaemia, testing whether one works better or causes fewer problems. It studies rituximab plus ibrutinib versus a standard mix of rituximab, cyclophosphamide, and dexamethasone (steroids).
BathAges 18 years+
Hear when a new Waldenström Macroglobulinemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for waldenström macroglobulinemia?
- Yes. Clin2 currently lists 18 recruiting waldenström macroglobulinemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a waldenström macroglobulinemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a waldenström macroglobulinemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.